International projects

Current

IMPROVE - 3Rs concepts to improve the quality of biomedical science (IMPROVE)
Duration: 1. 8. 2022 -
Evidence number: CA21139
Program: COST
Project leader: Dr.rer.nat., Ing. Kanďárová Helena, ERT
SAS cosolvers: Ing. Pôbiš Peter
Annotation: Awareness of the existence of a reproducibility and predictability crisis in biomedical science has increased in recent years. The reproducibility crisis refers to the problem that researchers struggle to replicate or reproduce scientific studies. There has been many publications reviewing why preclinical research is irreproducible and lack of predictability, pointing this to deficiencies in reporting and statistical practices. Confounding factors, which are part of the laboratory environment and will influence both the dependent and independent variables, continue to be identified, suggesting that our knowledge of their existence is far from complete. Better statistical methodology will play a central role in improving the reproducibility of science to produce robust and reproducible research. Another area of improvement is the development of novel methods to better define and assess replication success and improve predictability. Under this light, the development and introduction of new, powerful concepts for biomedical research is essential to reduce the production of non-reproducible and non-predictive data. This has immense scientific, economic and social significance. In this context, we propose that the findings and concepts from the 3Rs field can greatly help to improve biomedical research on several levels.Therefore, the main aim of the COST Action IMPROVE is:To establish a network which will work to refine, harmonise and promote 3Rs concepts, data and documents, in order to improve the quality of biomedical science.
Project website: https://www.cost.eu/actions/CA21139/
NETSKINMODELS - Engineering novel 3D organotypic skin models
Duration: 1. 5. 2022 -
Evidence number: CA21108
Program: COST
Project leader: Dr.rer.nat., Ing. Kanďárová Helena, ERT
SAS cosolvers: Ing. Pôbiš Peter
Annotation: Over the past years, investigative and experimental dermatology has developed various approaches, ranging from utilisation of ex-vivo skin tissues to establishment of reconstructed in-vitro and in-silico skin models as tools in both basic and translational skin research. These models have the strong potential to increase the significance of scientific and clinical outcomes and to reduce animal experimentation. Nevertheless, current skin models lack sophistication and standardisation, thereby hampering their wider acceptance by the scientific community and regulatory bodies. This is partly caused by a lack of cross talk between relevant stakeholders — regulatory bodies, basic scientists, clinicians, and industry — whereby advances in new technologies have not delivered their full potential in this field. In the proposed Action, interdisciplinary and intersectoral research and coordinated initiatives will drive the development and validation of standout sophisticated cell-based and computational skin models, including the development of artificial intelligence models for dermatological research. Furthermore, the Action has ambitions to develop ethical and sustainable reagents required for the elaboration of organotypic skin models, based on a strong partnership between network academia and industries. Harmonisation of scientific and technological knowledge and an enduring bottom-up dynamic in the field will be ensured by dissemination of leading-edge know-how among research intensive and research moderate European territories. Moreover, next-generation scientists will be trained for the long-term propagation and continued development of skin models. Action outcomes will turbocharge the field of skin models to meet rising scientific, clinical, economic, environmental and regulatory expectations, making Europe the epicentre of research in this field.
Project website: https://www.cost.eu/actions/CA21108/
ONTOX - Ontology-driven and artificial intelligence-based repeated dose toxicity testing of chemicals for next generation risk assessment
Duration: 1. 5. 2021 - 1. 5. 2026
Evidence number: H2020
Program: Horizont 2020
Project leader: Dr.rer.nat., Ing. Kanďárová Helena, ERT
SAS cosolvers: RNDr. Mach Mojmír, PhD.
Annotation: The vision of the ONTOX project is to provide a functional and sustainable solution for advancing human risk assessment of chemicals without the use of animals in line with the principles of 21st century toxicity testing and next-generation risk assessment. Specifically, ONTOX will deliver a generic strategy to create innovative new approach methodologies (NAMs) in order to predict systemic repeated dose toxicity effects that, upon the combination with tailored exposure assessment, will enable human risk assessment. This strategy can be applied to any type of chemical and systemic repeated dose toxicity effect. However, for proof-of-concept purposes, focus will be put on 6 specific NAMs addressing adversities in the liver (steatosis and cholestasis), kidneys (tubular necrosis and crystallopathy) and developing brain (neural tube closure and cognitive function defects) induced by a variety of chemicals, including from the pharmaceutical, cosmetics, food and biocide sectors. The 6 NAMs will each consist of a computational system based on cutting-edge artificial intelligence (AI) and will be primarily fed by available biological/mechanistic, toxicological/ epidemiological, physico-chemical and kinetic data. Data will be consecutively integrated in physiological maps, quantitative adverse outcome pathway networks and ontology frameworks. Data gaps, as identified by AI, will be filled by targeted state-of-the-art in vitro and in silico testing. The 6 NAMs will be evaluated and applied in collaboration with industrial and regulatory stakeholders in order to maximise end-user acceptance and regulatory confidence. This is anticipated to expedite implementation in risk assessment practice and to facilitate commercialisation. ONTOX will have a deep and long-lasting impact at many levels, in particular by consolidating Europe\'s world-leading position regarding the development, exploitation, regulation and application of animal-free methods for human risk assessment of chemicals.
Project website: www.ontox-project.eu
BenBedPhar - Bench to bedside transition for pharmacological regulation of NRF2 in noncommunicable diseases
Duration: 19. 10. 2021 - 18. 10. 2025
Evidence number: CA 20121
Program: COST
Project leader: RNDr. Bernátová Iveta, DrSc.
Annotation: Non-communicable diseases (NCDs) such as cancer, diabetes, cardiovascular, neurodegenerative, respiratory or immune diseases, account for 77% of all deaths in Europe and remain the most prevalent and without effective therapy. Networking among multidisciplinary teams that explore disease from a perspective of causative pathomechanisms rather than clinical symptoms is the most appropriate approach to overcome this problem. Such pathomechanisms imply the loss of homeostatic functions leading to the pathologic formation of reactive oxygen species, chronic inflammation, metabolic unbalance and proteinopathy. The transcription factor NRF2 is a master regulator of multiple cytoprotective responses and a key molecular link among many NCDs. It provides a unique strategy for drug development and repurposing that is now starting to be translated to the pharmacological and clinical arena. This Action build a network of excellence for integrating and spreading the existing knowledge and providing innovative services, drugs and tools related to NRF2-pharmacology, with the final goal of boosting the translation to the European industry sector. To achieve this, the Action has already gathered a wide set of professionals from different disciplines (medical chemistry, pharmacology, clinical research, molecular biology, bioinformatics, etc.) and sectors (universities, research centres, hospitals, biobanks, biotech and pharma companies, etc.). Thanks to COST tools the Action will boost the career of young researchers, wide participation, and spread excellence.
Partner countries: Austria, Bosnia and Herzegovina, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Egypt, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Japan, Latvia, Lithuania, Netherlands, North Macedonia, Poland, Portugal, Romania, Serbia, Slovakia, Slovenia, Spain, Switzerland, Turkey, United Kingdom, United States
EU-NETVAL International Thyroid Validation Study
Duration: 1. 1. 2021 - 1. 1. 2023
Evidence number:
Program: Multilaterálne - iné
Project leader: Dr.rer.nat., Ing. Kanďárová Helena, ERT
Annotation: Characterising, validating and standardising new non-animal methods and approaches are important steps towards their regulatory use and international adoption. Various thyroid methods, targeting different modes of action of thyroid disruption, are currently under validation by EURL ECVAM and its network of validation laboratories EU-NETVAL. Chemicals that disrupt thyroid homeostasis have the potential to be endocrine disruptors and thus associated with several adverse health effects.About EU-NETVAL:EU-NETVAL is a large network of 39 highly qualified test facilities across Europe, coordinated by the JRC to support the in vitro method validation process. It represents a wide range of expertise and competences and includes laboratories experienced in advanced in vitro procedures, biological test systems and measurement techniques.
Project website: https://ec.europa.eu/jrc/en/eurl/ecvam/alternative-methods-toxicity-testing/eu-netval
Anti-inflammatory effects of natural compounds isolated from Vietnam medicinal plants
Duration: 1. 4. 2020 - 31. 12. 2022
Evidence number: QTSK01.03/20-21
Program: Bilaterálne - iné
Project leader: PharmDr. Bauerová Katarína, PhD., DrSc.
SAS cosolvers: PharmDr. Dráfi František, PhD., MPH, Mgr. Chrastina Martin, PharmDr. Poništ Silvester, PhD., PharmDr. Taghdisiesfejír Mohsen
Other cosolvers: Pham Ngoc Khanh, Pharm
Annotation: Objectives of this project are as follows: - Screening of selected Vietnamese medicinal plants and natural compounds for in vitro anti-inflammatory activity; - Identification of mechanisms of action of the most bioactive compounds with anti-inflammatory activity using in vitro and in vivo methods (preferably model of adjuvant arthritis in rats).
Partner countries: Viet Nam
Anti-inflammatory effects of natural compounds isolated from Vietnam medicinal plants
Duration: 1. 1. 2020 - 31. 12. 2022
Evidence number:
Program: Bilaterálne - iné
Project leader: PharmDr. Bauerová Katarína, PhD., DrSc.
SKPTPHARMACOL - Collaboration on a complex pharmacological assessment of inflammatory diseases of the musculo-skeletal system and gastrointestinal tract on experimental animal models
Duration: 1. 1. 2019 - 31. 12. 2022
Evidence number: SK-PT-18-0022
Program: Bilaterálne - iné
Project leader: PharmDr. Bauerová Katarína, PhD., DrSc.
SAS cosolvers: PharmDr. Dráfi František, PhD., MPH, Mgr. Chrastina Martin, PharmDr. Poništ Silvester, PhD., Ing. Švík Karol, CSc., PharmDr. Taghdisiesfejír Mohsen
Other cosolvers: Prof. Bruno Miguel Nogueira Sepodes, PhD; Associate prof. João Pedro Fid
Annotation: Animal models have been used to study inflammatory diseases for almost a century. Our innovative approach in the research of inflammation and autoimmunity of the musculoskeletal and gastrointestinal tract is to use simultaneously multiple experimental models with well-known pathophysiology (i.e.: Collagen type-II-induced arthritis, Adjuvant-induced arthritis, Carrageenan induced oedema and trinitrobenzenesulfonic acid induced colitis). This enables us to better understand and describe the pharmacodynamic mode of action of experimental treatments approximately to human disease. Selected active substances studied on several models mentioned above, can bring us to deeper elucidation of mechanism of action. Moreover, the combination of substances studied together with an appropriate disease modifying anti-rheumatic drug may improve the standard treatment of inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel disease. The main outputs of this project will be to meet on our workplaces, sharing methodology and results analysis to create the proposal for future cooperation in between Slovakia and Portugal. In parallel we also plan to manage two bilateral conferences and to engage our PhD students and post-docs to this project. During the duration of this project we will seek for possibilities how to be a part of a multilateral and EU project network.
Partner countries: Portugal
Train -SafeMDs - Training Network for improving of safety of medical devices - focus on oral cavity
Duration: 1. 1. 2020 - 31. 12. 2022
Evidence number: DS-FR-19-0048
Program: Multilaterálne - iné
Project leader: Dr.rer.nat., Ing. Kanďárová Helena, ERT
Annotation: The TraiN-SafeMDs (i.e. Training Network for improving knowledge on the safety of medical devices) project brings together the unique expertise of the Czech National Institute of Public Health located in Prague (NIPH), the expertise of the Centre of Experimental Medicine in Bratislava (CEM) and the Austrian Institute of Technology in Vienna (AIT). The research team of the project has extensive expertise in tissue engineering of models of oral epithelium and/or in safety testing of different MD materials. The project also aims into the training of PhD students and early career scientist in the use of in vitro methods for the safety assessment of MDs.
Partner countries: Austria, Czech Republic
Project website: https://www.medicaldevicessafety.com/

Finished

LOGIC LAB - Molecular logic lab-on-a-vesicle for intracellular diagnostics
Duration: 1. 11. 2018 - 31. 10. 2022
Evidence number: ITN No. 813920
Program: Horizont 2020
Project leader: RNDr. Mach Mojmír, PhD.
SAS cosolvers: Ing. Račková Lucia, PhD.
Annotation: A dysfunction of cells lining the inner walls of blood vessels, i.e. the endothelium, is the primary cause of many lifestyle related diseases. According to the WHO, those diseases accounted for 60% of all deaths worldwide in 2005. Tailor-made diagnostic tools for early and reliable identification of endothelial dysfunction are urgently needed both in fundamental research and clinical routine, respectively.The Marie Skłodowska-Curie action LOGIC LAB objects to develop and characterize innovative molecular logic gates that can be applied as advanced diagnostic tools for parallel analyte sensing in live mammalian cells. Thereby, providing a unique method to discover endothelial dysfunction and the onset of diseases much easier and earlier than so far.LOGIC LAB creates a multi-faceted and multi-sectoral research environment for the next generation of scientists in order to establish a novel type of molecular logic sensors that reliably operate in biological media – a crucial requirement for their application i.e. as rapid and easy-to-handle tools for intracellular diagnostics.With excellent cross-disciplinary scientific and complementary training provided in the network, we aim to educate highly-skilled young scientists in the fields of chemistry, physics and biology, who will significantly strengthen the international research community in the domain of molecular logic sensing. Thus, in the long term, LOGIC LAB aims to finally bridge the gap between lab bench and biological or medical practice. It is this gap, that so far prevents a wide-ranging use of existing molecular logic gates e.g. for the diagnosis of lifestyle-associated diseases.
Partner countries: Germany, Ireland, Netherlands, Poland
CardioRNA - Catalysing transcriptomic research in cardiovascular disease
Duration: 3. 10. 2018 - 2. 10. 2022
Evidence number: CA17129
Program: COST
Project leader: doc. RNDr. Barteková Monika, PhD.
Annotation: This Action aims to create an interdisciplinary network to accelerate the understanding of transcriptomics in cardiovascular disease (CVD) and further the translation of experimental data into usable applications to improve personalized medicine in this field. CVD remains the leading cause of death worldwide and, despite continuous advances, better diagnostic and prognostic tools, as well as therapy, are needed. The human transcriptome, which is the set of all RNA produced in a cell, is much more complex than previously thought and the lack of dialogue between researchers and industrials and consensus on guidelines to generate data make it harder to compare and reproduce results. Currently, there is no network to address the complexity of transcriptomics in CVD, offering an advantage to this Action. It aims to provide opportunities for collaboration between stakeholders from complementary backgrounds, allowing the functions of different RNAs and their interactions to be more rapidly deciphered in the cardiovascular context for translation into the clinic. This Action will generate grant proposals to advance understanding of the transcriptome’s role in CVD and to translate findings into clinical applications, thus fostering personalized medicine and meeting a current public health challenge. CardioRNA will refine guidelines for transcriptomics investigations in CVD to increase reproducibility of results, facilitating clinical product development. It will disseminate knowledge and allow capacity-building through different types of meetings, prioritizing students and early career investigators. Thus, this Action will advance studies on cardiovascular transcriptomics, generate innovative projects and consolidate the leadership of European research groups in the field.
Partner countries: Austria, Belgium, Bosnia and Herzegovina, Croatia, Finland, France, Germany, Greece, Hungary, Italy, Luxembourg, Netherlands, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Spain, Sweden, Switzerland, United Kingdom
New Frontiers in Basic Cardiovascular Research 2022
Duration: 1. 1. 2021 - 30. 6. 2022
Evidence number: 22030337
Program: International Visegrad Found (IVF)
Project leader: doc. RNDr. Barteková Monika, PhD.
Annotation: The main aim of the project is organization of the 14th conference New Frontiers in Basic Cardiovascular Research planned to be held on June 16–18, 2021 in Bratislava, Slovakia. Cardiovascular diseases (CVD) are the leading cause of death worldwide, and it is estimated that by 2030, approximately 24 million people will die from CVD. In Europe, more than 14 million people suffer from CVD, the number of cases is increasing (300 000 per year), and the situation is particularly serious in new EU and V4 countries. Therefore, there is an urgent need to increase the knowledge in understanding the pathological mechanisms underlying development and progression of CVD, as well as to develop novel therapeutic strategies and their translation to clinical settings. This aim can be reached by sharing the knowledge among scientific community, as well as international cooperation and training. The tradition of these meetings lasts for more than 25 years; it started in 1994 as a bilateral Czechoslovakia-France meeting, but later on was open for other new EU countries and organized every second year in one of the V4 countries or France (Prague 1994, Smolenice 1996, Strasbourg 1998, Mariánské Lázně 2000, Smolenice 2002, Montpellier 2004, Debrecen 2006, Krakow 2008, Toulouse 2010, Hradec Králové 2012, Smolenice 2014, Paris 2016, Prague 2018). These meetings provided a unique platform for an exchange of scientific ideas and significantly contributed to collaboration among researchers from these countries.
Partner countries: Czech Republic, Hungary, Poland, Slovakia
Project website: https://newfrontiers2022.sav.sk/
EU-CARDIOPROTECT - Realising the therapeutic potential of novel cardioprotective therapies
Duration: 19. 10. 2017 - 18. 4. 2022
Evidence number: COST action ID CA16225
Program: COST
Project leader: MUDr. Ravingerová Táňa, DrSc., FIACS
SAS cosolvers: doc. RNDr. Barteková Monika, PhD., Mgr. Farkašová Veronika, PhD
Other cosolvers: Prof. Adriana Adameová, PhD, FaF UK
Annotation: The proposed COST Action will set up a pan-European Research Network of leading experts in cardioprotection, to jointly develop new initiatives and new strategies for finding innovative and more effective approaches to cardioprotection and for optimizing the pre-clinical and clinical evaluation of new cardioprotective therapies, so as to improve their translation into the clinical setting for patient benefit. The COST Action will co-ordinate and strengthen European research in the field of cardioprotection and accelerate scientific progress through the dissemination and sharing of new therapeutic targets, among network members and industrial partners, thereby facilitating the discovery of new cardioprotective therapies. By utilizing the joint expertise of different European network members we will investigate factors which confound the efficacy of new cardioprotection therapies including comorbidities (such as age, diabetes, and hypertension) and co-medications (such as anti-platelet therapies, statins and beta-blockers). Finally, we will set up a European network of research centers for multi-center laboratory testing of new cardioprotective therapies using small and large animal models of acute IRI in order to select those therapies most likely to succeed in the clinical setting. All aspects of this COST Action proposal require a critical mass of partners across a wide geographic distribution across Europe in order to deliver the objectives outlined in this proposal. The discovery of novel signaling pathways and targets underlying cardioprotection both within and outside the cardiomyocyte (WG1 NEW TARGETS), and the testing of different combinations of cardioprotective therapy (WG2 COMBINATION THERAPY) requires investigators with different experience and expertise across Europe. The ability to test the effect of confounders of cardioprotection (WG3 CONFOUNDERS) requires the expertise of different partners in the different co-morbidities and testing of co-medications. Finally, the most important objective of this COST Action proposal, requires the setting up of a Europe-wide research network for (a) multicenter testing of novel cardioprotective therapies using small and large animal models (WG4 CONSORTIUM) and (b) testing of novel cardioprotective therapies in proof-of-concept clinical studies and optimization of multi-center clinical outcome cardioprotection studies. By definition this requires a critical mass of research partners distributed across Europe.
Partner countries: Bosnia and Herzegovina, Czech Republic, Estonia, France, Germany, Greece, Hungary, Italy, Netherlands, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Spain, Switzerland, Turkey, United Kingdom
Anti-inflammatory effect of astaxanthin, sulforaphane and Crocus sativus extract evaluated in two rodent models of age related diseases.
Duration: 1. 1. 2018 - 30. 6. 2021
Evidence number:
Program: Medziakademická dohoda (MAD)
Project leader: PharmDr. Bauerová Katarína, PhD., DrSc.
SAS cosolvers: PharmDr. Bauerová Katarína, PhD., DrSc., PharmDr. Dráfi František, PhD., MPH, Mgr. Chrastina Martin, PharmDr. Poništ Silvester, PhD., Ing. Švík Karol, CSc.
Annotation: In this collaborative project, we would like to establish the animal model of CIOA in Balb/c mice. One of the aims of the proposal is to study the pathogenesis of before-mentioned disease and the development of joint changes in CIOA during treatment by selected antioxidants. Groups of CIOA-Balb/c mice will be treated with astaxanthin, sulforaphane and Crocus sativus extract. We will determine the levels of selected pro- and anti-inflammatory mediators and the phenotype of cells in the synovial extracts and sera as well as the histology changes after treatment. We expect, that after treatment of CIOA-mice, many of the observed parameters will be improved. The second rodent model used will be Lewis rats with induced arthritis (AA).
Partner countries: Bulgaria
Investigation of the mechanims involved in antiarrhythmic effects of melatonin
Duration: 1. 5. 2014 - 31. 12. 2020
Evidence number:
Program: Bilaterálne - iné
Project leader: RNDr. Tribulová Narcisa, DrSc.
SAS cosolvers: RNDr. Egan-Beňová Tamara, PhD., RNDr. Szeiffová Bačová Barbara, PhD.
Annotation: Cardiovascular diseases (CVD) are worldwide major cause of morbidity and mortality due to heart failure and incidence of malignant arrhythmias. Main risk factors of CVD are hypertension, diabetes, dyslipidemia, obesity, chronodisruption and stress. Aimed to prevent CVD and life-threatening arrhythmias it seems extremely important to investigate “pleiotropic” effects of endogenous candidate relevant to the CVD, i.e. neurohormone, melatonin. Neuro-humoral circadian rhythms are ‘chronically’ impaired and result in dys-synchrony of cellular cross talk in different tissues of individuals suffering from CVD. Lack of melatonin was repeatedly reported in patients with coronary heart disease. It appears that melatonin may serve as a new biomarker for a CVD risk. Melatonin in addition to its chrono-regulatory role exerts various “pleiotropic” actions: modulation of blood pressure and NO bioavailability, antioxidant, free radicals scavenging and anti-inflammatory effects, sympatholytic and anti-fibrotic potential and epigenetic regulatory function. Of note, previous experimental studies at both institutions showed clear-cut antiarrhythmic effect of melatonin in various pathophysiological conditions. Findings revealed that melatonin up-regulates myocardial connexin-43 (Cx43), protein of intercellular gap junction channels that are important for electrical impulse propagation and synchronization. Besides, melatonin modulates action potential duration suggesting its effect most likely on potassium and/or calcium channels. Nevertheless, there is a need to elucidate more in details the cellular and molecular mechanisms implicated in antiarrhythmic actions of melatonin
Partner countries: Argentina
Study of the triggering mechanisms and transmission of cardioprotective signals induced by noninvasive adaptive stimuli
Duration: 1. 1. 2018 - 31. 12. 2020
Evidence number: MAD SAV-AVCR-18-27
Program: Medziakademická dohoda (MAD)
Project leader: MUDr. Ravingerová Táňa, DrSc., FIACS
SAS cosolvers: Ing. Ferko Miroslav, PhD.
Annotation: Cardiovascular diseases are one of the leading causes of mortality in modern society and predicted to rise over the coming decades, due to aging population, longer survival after myocardial infarction, and incidence of civilization diseases. Research pointed out to the protective effects of phenomenon termed ischemic preconditioning (IPC), especially its novel clinically acceptable and safer forms. Currently, cellular mechanisms activated by stimuli like exercise, hypoxia and PC of the remote organ are not yet completely clear as compared with the classiccal IPC. For that reason, pathological animal models (myocardial ischemia, hypertension, d. mellitus, dyslipidemia) and aged animals will be used. Acute PC-like settings of above mentioned interventions, and their longer lasting adaptation modalities will be tested in the in vivo and the ex vivo rats using relevant methodology (combination of physiological, pharmacological and biochemical techniques). The results obtained in this project may lead to development of novel or modified therapeutic strategies to manage myocardial ischemia in patients.
Partner countries: Czech Republic
Study the role of iron oxide nanoparticles in a model of hypertension and comorbid Alzheimer\'s disease
Duration: 1. 1. 2018 - 31. 12. 2020
Evidence number: SAV-BAV-18-11
Program: Medziakademická dohoda (MAD)
Project leader: RNDr. Bernátová Iveta, DrSc.
SAS cosolvers: RNDr. Bališ Peter, PhD., Mgr. Svoreň Pavol
Annotation: Slovak partner of this project is focused on investigations of the influence of the biocompatible ultra-small superparamagnetic iron oxide nanoparticles (USPIONs), which are suitable for clinical applications, on function and structure of the arterial wall and the heart in rats with high blood pressure. Bulgarian partner is focused on the role of USPIONs on development of Alzheimer´s disease in a comorbid hypertension. The aim is to investigate if chronic high blood pressure can facilitate the USPIONs uptake in the arterial wall, heart and brain and thus to modify cardiovascular function (including blood pressure regulation) and to induce metabolic disorders. We will determine oxidative and nitrosative damage, inflammatory markers, including proinflammatory cytokines and TNF-alpha in the vasculature, heart, hippocampus and the frontal cortex of normotensive, hypertensive and streptozotocin-treated spontaneously hypertensive rats, a model of comorbid hypertension and Alzheimer´s disease.
Partner countries: Bulgaria
MuTaLig - Multi-target paradigm for innovative ligand identification in the drug discovery process
Duration: 4. 12. 2015 - 29. 10. 2020
Evidence number: COST CA15135
Program: COST
Project leader: RNDr. Májeková Magdaléna, PhD.
SAS cosolvers: RNDr. Balleková Jana, Ing. Šoltésová Prnová Marta, PhD., Ing. Štefek Milan, CSc.
Annotation: The aim of this COST Action is to join highly-qualified research teams working in disciplines around the field of medicinal chemistry, into a novel network devoted to the multi-target issue in drug discovery. The choice of this theme is related to its marked multidisciplinary character, which can ensure a strong interaction among all COST Action participants. Currently, an important and emerging issue in modern drug discovery is to design novel or identify existing bioactive compounds, endowed with the capability to interact selectively with two or more macromolecular targets, exerting their effects against certain therapeutic goals in a synergic fashion. This leading concept stimulated this COST Action focusing on novel ligands able to recognize selected multiple targets, to promote closer scientific links among European research groups involved in medicinal chemistry field at both academic and industrial level. The research competencies of the network will span around medicinal chemistry, from synthetic chemistry, natural products and biophysics to theoretical chemistry, molecular modelling and biological screening.
Project website: http://www.mutalig.eu/
GLUCOLIPOTOX - Targeting Molecular Pathways of Glucolipotoxicity by a Novel Carboxymethylated Mercaptotriazinoindole Inhibitor of Aldo-Keto Reductase AKR1B1 In Diabetes, Inflammation and Age-related Neurodegeneration
Duration: 1. 5. 2016 - 30. 4. 2019
Evidence number: SAS-TUBITAK JRP 2015/7-Turecko
Program: Bilaterálne - iné
Project leader: Ing. Štefek Milan, CSc.
SAS cosolvers: RNDr. Balleková Jana, MVDr. Bezek Štefan, DrSc., RNDr. Fabianová Kamila, PhD., RNDr. Gálik Ján, CSc., RNDr. Kováčiková Lucia, PhD., RNDr. Májeková Magdaléna, PhD., RNDr. Martončíková Marcela, PhD., RNDr. Račeková Enikö, CSc., Ing. Račková Lucia, PhD., Ing. Šoltésová Prnová Marta, PhD., Ing. Švík Karol, CSc.
Annotation: Novel therapeutic strategies for attenuating glucolipotoxicity leading to development of chronic diabetic complications, inflammatory disorders and age-related neurodegeneration are urgently needed for diabetic population. Aldo-keto reductases have been implicated in pathophysiology of diabetic complications mainly via functioning of aldose reductase (ALR2, AKR1B1) in the polyol pathway. These enzymes are also known to reduce the lipid peroxidation-derived aldehydes, such as 4-hydroxy-trans-2-nonenal (HNE) and their glutathione conjugates (e.g. GS-HNE), to corresponding alcohols which mediate the inflammatory signals. In addition, diabetics are prone to accelerated neurodegeneration. The main scientific goal of the joint project comprises a multidisciplinary approach to the detailed characterization of functional effects of CMTI, a novel carboxymethylated mercapto-triazinoindole inhibitor of aldo-keto reductases, on multiple glucolipotoxicity pathways. The aim of the study will be reached through specific tasks including in silico modelling, studies under in vitro conditions at the level of isolated enzymes and cells, ex vivo studies on isolated rat eye lenses and sciatic nerves, and in vivo studies in models of STZ diabetic rats, ZDF rats and experimental colitis. We believe that with the projected experiments we will for the first time firmly establish whether CMTI has ability to interfere with molecular mechanisms of glycolipotoxicity and whether these effects are mediated by the inhibition of aldo-keto reductases. Therapeutic potential of CMTI is expected in relation to late diabetic complications, inflammatory disorders and age-related neurodegeneration. The results will contribute vitally to a preclinical evaluation of CMTI as a potential drug.
Partner countries: Turkey
-
Duration: 1. 4. 2015 - 31. 12. 2017
Evidence number:
Program: Medziústavná dohoda
Project leader: MUDr. Riečanský Igor, PhD.
Evaluation of Quercetin and Green Tea in combination with Methotrexate for arthritis therapy (Acronym: PhytoArt 2.0)
Duration: 1. 1. 2016 - 31. 12. 2017
Evidence number: CNR-SAV 2016
Program: Bilaterálne - iné
Project leader: PharmDr. Bauerová Katarína, PhD., DrSc.
Partner countries: Italy
Mechanisms of radiation injury to the heart. Preventive drug treatment.
Duration: 1. 1. 2014 - 31. 12. 2017
Evidence number:
Program: Multilaterálne - iné
Project leader: D.h.c., Prof., MUDr. Slezák Ján, DrSc., FIACS
Partner countries: Canada, Greece, China, United States
Multidisciplinary analysis of the combined effects of thyroid hormones and n-3 polyunsaturated fatty acids in rats
Duration: 1. 1. 2015 - 31. 12. 2017
Evidence number:
Program: Medziakademická dohoda (MAD)
Project leader: RNDr. Tribulová Narcisa, DrSc.
SAS cosolvers: RNDr. Egan-Beňová Tamara, PhD., RNDr. Szeiffová Bačová Barbara, PhD., Mgr. Viczenczová Csilla, PhD.
Annotation: Thyroid hormones (TH) play a crucial role in healthy organisms, but profound alterations of their levels can affect metabolic and signaling processes in different tissues. We will use hyper- and hypothyroid rats as “model of a diseased organism” and analyze whether and how n-3 PUFA long term administration will ameliorate TH-induced pathophysiological changes. We will investigate skeletal and cardiac muscle tissue remodeling, changes in serum lipids and in body fat distribution, key enzymes of TH metabolism, oxidative stress in the whole organism and within the cell. We will focus on myosin heavy chain composition, distribution and phosphorylation of connexin-43, cellular calcium handling, membrane anisotropy, mitochondrial functions and related signaling pathways including cell death and antioxidant defense. As n-3 PUFA possess multiple sites of potential action, we believe that our complex research will contribute to a better understanding of molecular mechanisms governing n-3 PUFA actions and to their more effective application in the prevention of pathological symptoms in man.
Stress-induced pressor responses: endothelial factors vs. central regulation of sympathetic tone
Duration: 1. 1. 2016 - 31. 12. 2017
Evidence number: SAV-AV ČR 16-18
Program: Medziakademická dohoda (MAD)
Project leader: RNDr. Bernátová Iveta, DrSc.
SAS cosolvers: RNDr. Bališ Peter, PhD., Mgr. Kluknavský Michal, PhD., MUDr. RNDr. Púzserová Angelika, PhD., Mgr. Svoreň Pavol
Annotation: Acute stress is considered to be a factor that may participate in stroke and heart attack. Mechanisms involved may be associated with inadequate acute stress-induced elevation of blood pressure (BP). On the basis of our previous joint research the aim of this project is to reveal differences in mechanisms involved in acute stress-induced pressor responses in adult normotensive and spontaneously hypertensive (SHR) rats. We will determine the role of nitric oxide (NO) in central regulation of sympathetic tone as well as the role of endothelium-derived factors (EDFs) such as NO, superoxide and hydrogen sulfide, in modulation of stress-induced BP responses. Acute stress will be induced by air-jet to the face of the rat. The effect of particular BP regulation systems will be investigated using inhibitors specific for the given system such as pentolinium (SNS), tempol (ROS), selective inhibitors of nNOS, iNOS and eNOS and other substances to inhibit selected EDFs. Resolving differences in acute stress-induced pressor responses could provide mechanism for selective prevention of dangerous stress-induced BP increase in hypertensive subjects and thus in prevention of stress-provoked stroke and heart attack.
Partner countries: Czech Republic
Sensorimotor - Postural and core stability in association with respiratory functions in healthy and lung transplant individuals
Duration: 1. 1. 2016 - 31. 12. 2017
Evidence number: SK-AT-2015-0031
Program: Bilaterálne - iné
Project leader: Ing. Hlavačka František, CSc.
SAS cosolvers: RNDr. Bzdúšková Diana, PhD., Mgr. Hirjaková Zuzana, PhD., RNDr. Kimijanová Jana, PhD., Mgr. Šuttová Kristína, PhD.
Annotation: Lung transplantation has been shown to be effective as a treatment for fatal and severecardiopulmonary diseases. In addition to survival, one goal of performing lung transplantation isimprovement in functioning and health. Several factors contribute to the maximal work capacityachievable after transplantation. Before surgery, patients are usually debilitated from the primarydisease and long-term inactivity, and the unavoidable complications of allograft transplantation,mainly lung resection, and toxic effects of immunosuppressant therapy contribute to the reducedfunctional capacity. While numerous investigators have described the features of the respiratoryand skeletal muscle function before and after surgery, little information is currently availableregarding the functional outcomes, such as strength and power, speed of step initiation, posturaland core stability, and so forth. It is mainly due to a lack of a standard evaluation system of theseabilities. Recently, we have developed new methodology for assessment of postural sway andbreathing movements of the chest using wireless accelerometers. Yet, it was not tested in lungtransplant patients and no investigations related to the relationship of variables of neuromuscularand cardiorespiratory functions were carried out. Therefore, we will assess postural and corestability, muscle strength and cardiorespiratory functions using posturography, surface EMG,accelerometry and clinical tests in healthy young and elderly individuals and lung transplantpatients. The findings will serve as a basis for better understanding of association betweenrelated variables in these people. As a result of the project will be elaborated methodology fortesting of neuromuscular and cardiorespiratory functions using novel techniques specificallydesigned for target population. Such objective and less time-consuming assessment can be wellfitted in an out-patients department and complement so existing diagnostic methods.
Partner countries: Austria
Effect of pathological states on cardiac resistance against myocardial ischemia: study of molecular mechanisms and novel approaches to cardioprotection
Duration: 1. 1. 2015 - 31. 12. 2017
Evidence number:
Program: Medziakademická dohoda (MAD)
Project leader: MUDr. Ravingerová Táňa, DrSc., FIACS
SAS cosolvers: RNDr. Čarnická Slávka, PhD, Mgr. Farkašová Veronika, PhD, Ing. Ferko Miroslav, PhD., Ing. Gablovský Ivan, Mgr. Jašová Magdaléna, PhD., Mgr. Kancírová Ivana, PhD., Mgr. Kindernay Lucia, PhD., Mgr. Muráriková Martina, PhD., Ing. Ziegelhöffer Attila, DrSc.
Annotation: Previously, we showed a negative impact of civilization diseases (hypertension, metabolic disorders) on adaptive mechanisms in the heart and its survival under conditions of acute ischemia/reperfusion (I/R). Comorbidities and age- and gender-related changes blunt protective cell signaling of ischemic preconditioning (PC) leading to acceleration of necrotic and apoptotic processes, impaired function of mitochondria and energy production. The project is focused on the study of molecular mechanisms that alter innate cardioprotection in the diseased myocardium and on possibilities to reactivate its adaptive potential. We will explore effects of novel forms of PC, so called „remote“ PC (induced by limb ischemia) that are less technically demanding and can be used in clinical practice, e.g., in elder patients with acute myocardial infarction. Investigation of mechanisms of „remote“ PC will enable its pharmacological simulation, e.g., using pleiotropic (other than primary) effects of PPAR agonists or their combination with PC that can facilitate stimulatory effect on cardiac resistance against I/R.
Partner countries: Czech Republic
BIOMAMI - Magnesium Nanocomposites for Biodegradable Medical Implants
Duration: 1. 11. 2014 - 31. 10. 2017
Evidence number: JRP 2014/5
Program: Medziakademická dohoda (MAD)
Project leader: doc. RNDr. Pecháňová Oľga, DrSc.
Other cosolvers: Scientific and Technological Research Council of Turkey, Turecko
Partner countries: Turkey
An integrated European platform for pancreas cancer research: from basic science to clinical and public interventions for a rare disease
Duration: 14. 12. 2012 - 13. 12. 2016
Evidence number: ESSEM COST Action BM1204
Program: COST
Project leader: Ing. Ďurišová Mária, DrSc.
COST BM1204 - COST BM1204 : An integrated European platform for pancreas cancer research: from basic science to clinical and public health interventions for a rare disease
Duration: 16. 7. 2012 - 13. 12. 2016
Evidence number:
Program: COST
Project leader: RNDr. Májeková Magdaléna, PhD.
SAS cosolvers: RNDr. Balleková Jana, Mgr. Miláčková Ivana, Ing. Šoltésová Prnová Marta, PhD., Ing. Štefek Milan, CSc.
Other cosolvers: Pavol Májek (Ústav analytickej chémie, Fakulta chemickej a potravinárskej technológie STU)
Annotation: To present the method based on molecular modeling, which is connected with potential molecular target for pancreas cancer detection, treatment and prevention. The aldo-keto reductases (AKRs) are enzymes with beneficial physiological functions, but they can play also a negative role by various pathologic processes. Our aim is to elaborate models of AKR subtypes specific for pancreatic cancer, drug design and characterization of novel aldo-keto reductase inhibitors of indole type with potential therapeutic effect in relation to pancreatic cancer and to evaluate their use together with biochemical experiments.
Partner countries: Belgium, Germany, Greece, Hungary, Ireland, Israel, Italy, Lithuania, Netherlands
Project website: http://eupancreas.com
EU-ROS - EU-ROS: The European Network on Oxidative Stress and Redox Biology Research
Duration: 1. 6. 2013 - 31. 5. 2016
Evidence number:
Program: COST
Project leader: doc. RNDr. Pecháňová Oľga, DrSc.
-
Duration: 1. 1. 2013 - 31. 12. 2015
Evidence number: CNR-SAV 2013
Program: Bilaterálne - iné
Project leader: PharmDr. Bauerová Katarína, PhD., DrSc.
Partner countries: Italy, Slovakia
Role of the systemic inflammatory processes in the development of oxidative stress in the brain of arthritic subjects. Evaluation of experimental therapy based on new carnosine preparations
Duration: 1. 1. 2013 - 31. 12. 2015
Evidence number: RAMS-SAV 2013
Program: Bilaterálne - iné
Project leader: PharmDr. Bauerová Katarína, PhD., DrSc.
Sensory Integration for stance and gait in healthy people and neurological patients.
Duration: 1. 2. 2013 - 31. 12. 2015
Evidence number:
Program: Medziústavná dohoda
Project leader: Ing. Hlavačka František, CSc.
SAS cosolvers: Mgr. Hirjaková Zuzana, PhD., RNDr. Kimijanová Jana, PhD., Mgr. Šuttová Kristína, PhD.
Partner countries: Slovakia, United States
Study of cellular and molecular mechamisms involved in cardioprotective effects of red palm oil.
Duration: 1. 1. 2010 - 31. 12. 2015
Evidence number:
Program: Bilaterálne - iné
Project leader: RNDr. Tribulová Narcisa, DrSc.
SAS cosolvers: RNDr. Mitašíková (Fialová) Marcela, doc. MUDr. Radošinská Jana, PhD., MUDr. Ravingerová Táňa, DrSc., FIACS, RNDr. Szeiffová Bačová Barbara, PhD.
Annotation: The link between dietary fats and cardiovascular disease has initiated a growing interest in dietary red palm oil (RPO) research. Oxidative stress and the severity or progression of disease has stimulated further interest in the potential role of RPO (a cocktail of natural antioxidants) to improve redox status. Currently no data exists indicating that RPO supplementation will affect propensity of the heart to malignant arrhythmias in humans or experimental animals. However, it has been reported that palm oils may have some anti-arrhythmic properties. Purpose of the project is to investigate whether RPO intake may offer protection of heart function and protection from malignant arrhythmias as well as to investigate cellular and molecular mechanisms involved in.
Partner countries: South Africa
KLINIPREC - Study of clinically applicable novel forms of preconditioning as an alternative method of cardiac protection against acute ischemia in the organism challenged with civilization diseases
Duration: 1. 1. 2015 - 31. 12. 2015
Evidence number: APVV-SK-CZ-2013-075
Program: Medzivládna dohoda
Project leader: MUDr. Ravingerová Táňa, DrSc., FIACS
SAS cosolvers: RNDr. Čarnická Slávka, PhD, Mgr. Farkašová Veronika, PhD, Ing. Ferko Miroslav, PhD., Mgr. Muráriková Martina, PhD., Ing. Ziegelhöffer Attila, DrSc.
Annotation: In the previous studies, we have found that so called civilization diseases (hypertension, metabolic disorders) have a negative impact on the adaptive mechanisms of the heart’s own resistance against ischemia and, therefore, can alter heart survival under conditions of ischemia/reperfusion (I/R). Coexistence of several pathologies, as well as the changes related to age and gender differences, suppress cell signaling involved in protective effects of classical ischemic preconditioning (PC). The latter leads to acceleration of necrotic and apoptotic processes in cardiomyocytes during I/R, reduces energy production and promotes enhanced arrhythmogenesis. The project is focused on the study of the possibilities to modulate the intensity and/or forms of adaptive stimuli with the aim to reactivate adaptive potential in pathologically altered (remodelled) myocardium as an alternative approach to cardiac protection against acute ischemia. We will explore acute and delayed effects of novel forms of PC, so called „remote“ PC (induced by ischemia of other organ, e.g., limb) that are less technically demanding and can be used in the clinical situations, in particular, in patients with acute myocardial infarction indicated for revascularization interventions or cardiosurgery. Investigation of molecular mechanisms of „remote“ PC (including its effects on the mitochondrial function, regulation of energy metabolism and cell death processes) will enable its simulation by pharmacological means alone or use their combination with PC that can strengthen the overall stimulatory effect on the myocardial resistance against subsequent ischemia.
Partner countries: Czech Republic
Ochrana srdca pr - Investigation of the cardioprotection against injury and malignant arrhythmias induced by altered thyroid status.
Duration: 1. 1. 2014 - 31. 12. 2015
Evidence number: SK-CZ-2013-0256
Program: Medzivládna dohoda
Project leader: RNDr. Tribulová Narcisa, DrSc.
SAS cosolvers: RNDr. Egan-Beňová Tamara, PhD., doc. MUDr. Radošinská Jana, PhD., RNDr. Szeiffová Bačová Barbara, PhD., Mgr. Viczenczová Csilla, PhD.
Partner countries: Czech Republic
The characterization and functional effects of quercetin and its derivative CHNQ, a potent aldo keto reductase inhibitor, in colorectal cancer
Duration: 1. 1. 2013 - 31. 12. 2015
Evidence number: 113S006
Program: Bilaterálne - iné
Project leader: Ing. Štefek Milan, CSc.
Partner countries: Turkey
Effects of antioxidants on metabolic syndrome: reactive oxygen species/nitric oxide balance
Duration: 1. 1. 2007 - 31. 12. 2015
Evidence number:
Program: Medziústavná dohoda
Project leader: doc. RNDr. Pecháňová Oľga, DrSc.
SAS cosolvers: MVDr. Barta Andrej, PhD., RNDr. Klimentová Jana, PhD., MUDr. RNDr. Paulis Ľudovít, PhD. MPH., RNDr. Vranková Stanislava, PhD.
Annotation: On the basis of the mutual interests and of the previous fruitful bilateral agreement, we cooperate in the research focused on the analysis of mechanisms leading to the metabolic syndrome. The possibilities of prevention of the risk factors leading to the metabolic syndrome are studied particularly. The coopeartion is based on unformal exchange of methods, results and experimental data, on common experiments performed during mutal study and on preparation of shared publications.
Partner countries: Czech Republic, Japan
Intracellular signaling pathways and nuclear transcription factor activation in cardiac adaptation to ischemia/reperfusion injury
Duration: 1. 1. 2011 - 31. 12. 2015
Evidence number:
Program: Bilaterálne - iné
Project leader: MUDr. Ravingerová Táňa, DrSc., FIACS
SAS cosolvers: RNDr. Čarnická Slávka, PhD, Mgr. Farkašová Veronika, PhD, RNDr. Nemčeková Martina, Ing. Pancza Dezider
Other cosolvers: Prof. Antigone Lazou, Tara Kelly, PhD, RNDr. Eleftheria Barlaka, RNDr. Eleftheria Galatou
Annotation: Peroxisome proliferator-activated receptors (PPAR), ligand-activated transcription factors, belong to the nuclear hormone receptor superfamily regulating expression of genes involved in different aspects of lipid metabolism, energy production and inflammation. PPAR-alpha isoform has been recognized as the central regulator of lipid catabolism, whereas PPAR-gamma regulates lipid anabolism or storage. Until recently, the function of PPAR-beta/delta isoform was relatively less explored. In the normal adult myocardium, activation of PPAR-alpha promotes mitochondrial fatty acids oxidation as the primary pathway of ATP generation. Under different physiological and pathological conditions, PPAR-alpha modulates expression of genes that determine myocardial substrate switch from fatty acids to glucose aimed at the maintenance of energy production to preserve basic cardiac function. However, the role of PPARs in the pathogenesis of a variety of heart disorders including myocardial ischemia still remains unclear. Although PPAR-alpha and PPAR-gamma synthetic agonists, hypolipidemic and antidiabetic drugs, respectively, have been reported to protect the heart against ischemia/reperfusion injury, it is still a matter of debate whether PPAR activation plays a beneficial or detrimental role in myocardial response to ischemia, in particular, in pathological conditions. The project is focused on the study of the role of PPAR modulation in the mechanisms of cardiac response to ischemia in normal and diseased heart. Specifically, it will address the role of PPAR-beta in susceptibility to ischemia in the diabetic myocardium. Finally, the involvement of PPARs in the mechanisms of pleiotropic (lipid-independent) cardioprotective effects of some hypolipidemic and antidiabetic drugs, as well as in the cellular mechanisms of endogenous cardioprotection will be also investigated. Anticipated results will contribute to identification of PPARs as a novel therapeutical target in treatment of heart diseases
Partner countries: Greece
GLIADIN - -
Duration: 1. 1. 2012 - 31. 12. 2015
Evidence number:
Program: Bilaterálne - iné
Project leader: RNDr. Gajdošíková Alena
Partner countries: Austria
COST CM1103 Structure-based drug design for diagnosis and treatment of neurological diseases
Duration: 28. 11. 2011 - 27. 11. 2015
Evidence number: COST CM1103
Program: COST
Project leader: RNDr. Májeková Magdaléna, PhD.
SAS cosolvers: RNDr. Balleková Jana, Ing. Šoltésová Prnová Marta, PhD., Ing. Štefek Milan, CSc.
Annotation: The therapy of neuropsychiatric disorders is limited by the high variability of symptoms and behavioural disturbances. Few drugs are available to address specific subsets of neurological/mental symptoms, and none to aid in diagnosis or to stop the progress of neurodegenerative disorders.Neurotransmitters such as dopamine and serotonin play a central role in the pathophysiology of major neuropsychiatric illnesses, such as anxiety and mood disorders, schizophrenia, autism-spectrum disorders, Parkinson’s disease, epilepsy, and dementias. Neurotransmitter-binding proteins such as receptors, transporters and common metabolic enzymes are the starting points for development of tools to diagnose and drugs to treat specific clusters of symptoms.Structure-based drug design, synthetic chemistry and biological characterisation will inform the choice of lead compounds to treat select subsets of brain malfunction. COST collaboration facilitates the cross-disciplinary interaction for discovery of promiscuous drugs for diagnosis and treatment of complex brain diseases. In addition to addressing a clinical need, bringing together academic scientists with a broad range of techniques and knowledge, this close collaboration will enrich interdisciplinary scientific training to design chemical tools for neuropathology across Europe, and provide lead compounds with the potential for transfer to the European pharmaceutical industry.
Partner countries: Austria, Belgium, Croatia, Czech Republic, Denmark, Germany, Ireland, Malta, Poland, Portugal, Serbia, Slovakia, Slovenia, Spain, Turkey, United Kingdom
Gasotransmitters: from basic science to therapeutic applications
Duration: 1. 5. 2011 - 1. 5. 2015
Evidence number: COST BM1005
Program: COST
Project leader: doc. RNDr. Pecháňová Oľga, DrSc.
Partner countries: Austria, Belgium, France, Germany, Greece, Netherlands, Norway, Poland, Portugal, Spain, Turkey, United Kingdom
Nové hybridné mo - Biocatalytic development of novel hybrid molecules with improved cardioprotective properties: Targeting the Na+,K+-ATPase
Duration: 1. 1. 2013 - 31. 12. 2014
Evidence number: SK-GR-0060-11
Program: Medzivládna dohoda
Project leader: RNDr. Vrbjar Norbert, CSc.
SAS cosolvers: MUDr., Ing. Jendruchová (Javorková) Veronika, PhD., Mgr. Kaločayová Barbora, PhD., RNDr. Mézešová Lucia, RNDr. Vlkovičová Jana, PhD.
Annotation: The aim of the project is to generate novel hybrid molecules, which will be able to control hypertension and prevent hypertension-induced cardiovascular damage. To achieve this, hybrid molecules will be designed to retain the ability to block the angiotensin II effect, protect the Na,K-ATPase against hypertension and adopt increased antioxidant ability. Oxidative stress is a well-known mechanism that is responsible for the development of vascular damage. Although it is believed that lowering blood pressure is the main protective mechanism of antihypertensive treatments, treatments that interfere with oxidative stress could be useful tools for management of these individuals. The Na+,K+-ATPase is a housekeeping enzyme that energizes the membrane potential in almost all animal cells, and it is very sensitive to pressure overload in various experimental models of hypertension. Previous studies of the Slovakian research group involved in the proposed project documented the partial protective effect of natural flavonoids against hypertension-induced deteriorations of the Na,K-ATPase in the heart and kidney. In the framework of the project the complementary experience of the Greek group in the isolation of natural products, biocatalytic preparation of conjugated molecules and oxidative stress as of the Slovak groups in the biochemical evaluation of the generated compounds and their effects in various pathological situations could result in the development of bioactive compounds that will provide enhanced protection of the Na,K-ATPase against hypertension combining the positive effect of antihypertensive molecules and natural antioxidants.
Partner countries: Greece
Study of endogenous cardioprotective mechanisms against myocardial ischemia
Duration: 1. 1. 2009 - 31. 12. 2014
Evidence number:
Program: Medziakademická dohoda (MAD)
Project leader: MUDr. Ravingerová Táňa, DrSc., FIACS
SAS cosolvers: doc. RNDr. Barteková Monika, PhD., RNDr. Čarnická Slávka, PhD, Ing. Ferko Miroslav, PhD., Mgr. Muráriková Martina, PhD., Ing. Pancza Dezider, MUDr. Styk Ján, CSc., Ing. Ziegelhöffer Attila, DrSc.
Other cosolvers: Fyziologický ústav AV ČR, Praha, ČR - Prof. RNDr. F. Kolář, CSc., Prof. B. Ošťádal, Dr. I. Ošťádalová, Dr. J. Neckář, Mgr. K. Slamová, Ing. F. Papoušek, P. Mandíková,
Partner countries: Czech Republic
Investigation of the effects of omega-3 fatty acids and red palm oil in rats with altered thyroid status
Duration: 1. 1. 2012 - 31. 12. 2014
Evidence number:
Program: Medziakademická dohoda (MAD)
Project leader: RNDr. Tribulová Narcisa, DrSc.
SAS cosolvers: RNDr. Egan-Beňová Tamara, PhD., doc. MUDr. Radošinská Jana, PhD., RNDr. Szeiffová Bačová Barbara, PhD., Mgr. Viczenczová Csilla, PhD.
Partner countries: Czech Republic
Chemistry of non-enzymatic protein modification – modulation of protein structure and function
Duration: 1. 11. 2010 - 31. 10. 2014
Evidence number: COST action CM 1001
Program: COST
Project leader: RNDr. Horáková Ľubica, PhD.
Partner countries: Belgium, Croatia, Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary, Israel, Italy, Latvia, Lithuania, Netherlands, North Macedonia, Poland, Portugal, Romania, Serbia, Slovakia, Spain, Sweden, Switzerland, Turkey, United Kingdom
NF 2014 - IVF grant New Frontiers in Basic Cardiovascular Research 2014
Duration: 1. 2. 2014 - 30. 7. 2014
Evidence number: IVF 11340240
Program: Iné
Project leader: MUDr. Ravingerová Táňa, DrSc., FIACS
SAS cosolvers: Ing. Ferko Miroslav, PhD.
Annotation: The project aim was the organization of the 11th cardiovascular science meeting of New EU (mostly V4) countries and France. Cardiovascular diseases are major cause of death in the whole Europe including V4 countries. The successful battle with them requires understanding of their molecular basis and elaboration of novel approaches to their treatment. Hence, there is an urgent need for researchers to collaborate across the borders to ensure effective fight with this epidemy. The conference provides a unique platform for an exchange of recent ideas and strengthening of collaboration between participants from V4 countries, other new EU countries and a traditional EU partner – France. In addition, it helps to find partners for joint applications for international (EU) research grant projects. Furthermore, this is an excellent opportunity for PhD students and young scientists (YS, Post-Docs) to present and discuss their results with the peers. To increase their motivation, a special competition of YS (with the best presentations given awards) is a part of the program. This also offers opportunities to plan student exchanges and study stays in the laboratories of the V4 region and in France.
Partner countries: Czech Republic, France, Hungary, Poland
Project website: www.newfrontiers2014.sav.sk
Cooperation agreement between INPP SAS and Faculty of Psychology, University of Vienna
Duration: 15. 5. 2011 - 31. 12. 2013
Evidence number:
Program: Medziústavná dohoda
Project leader: MUDr. Riečanský Igor, PhD.
SAS cosolvers: Ing. Bendžala Štefan, Mgr. Budáč Stanislav, RNDr. Cimrová Barbora, PhD., MUDr. Jagla Fedor, CSc., doc. PaedDr. RNDr. Katina Stanislav, PhD., Mgr. Roháriková Veronika, PhDr. Špajdel Marián, PhD.
Annotation: Cooperation agreement is based on shared research interests, methodological focus as well as fruitful bilateral projects of research cooperation (2007-2011). The cooperating organizations declared their willingness to extend their cooperation in the field of social, cognitive and affective neuroscience for future period. The cooperation includes mutual study visits, sharing of methodological resources and experimental data, preparation of international research projects, preparation and accomplishment of common experiments, preparation of shared publications, organization of scientific events.
Partner countries: Austria
Metabolic syndrome: inflammation in hypertension and effect of polyphenols
Duration: 15. 6. 2010 - 31. 12. 2013
Evidence number:
Program: Medziústavná dohoda
Project leader: doc. RNDr. Pecháňová Oľga, DrSc.
Study of interactions between reactive oxygen species and nitric oxide in search for novel mechanisms of hypertension
Duration: 1. 1. 2011 - 31. 12. 2013
Evidence number: SAS-NSC JRP 2010/01
Program: Bilaterálne - iné
Project leader: doc. RNDr. Dovinová Ima, PhD.
SAS cosolvers: RNDr. Bališ Peter, PhD., RNDr. Barančík Miroslav, DrSc., RNDr. Čačányiová Soňa, PhD., RNDr. Drobná Magdaléna, PhD., Mgr. Grešová Linda, RNDr. Kristek František, DrSc., Mgr. Majzúnová Miroslava, PhD., Mgr. Šestáková Natália, Ing. Zorad Štefan, CSc.
Annotation: The aim of the project is to study interplay between superoxide dismutases (SOD) and NO synthases (NOS) in pathogenesis of hypertension. The project is focus on (a) study of interactions between ROS and NO, at both peripheral level and in the rostral ventrolateral medulla of the brain stem using inhibition or overexpression of genes encoding NOS/SOD isoforms, (b) use of PPAR gama activator- rosiglitazon, to investigate its influence on NO system (c) delineation of the redox-sensitive intracellular signaling molecules as triggers of protein kinase signaling pathways involved in hypertension.
Partner countries: Taiwan
Investigation of the cardioprotection from injury and malignant arrhythmias induced by altered thyroid statuses.
Duration: 1. 1. 2012 - 31. 12. 2013
Evidence number: APVV-SK-CZ-0027-11
Program: Medzivládna dohoda
Project leader: RNDr. Tribulová Narcisa, DrSc.
Partner countries: Czech Republic
REINOC - Effect of renin and (pro)renin receptor inhibition on cardiovascular system with special focus on gasotransmitters
Duration: 1. 3. 2012 - 31. 12. 2013
Evidence number: SK-SRB-0038-11
Program: Bilaterálne - iné
Project leader: doc. RNDr. Pecháňová Oľga, DrSc.
Partner countries: Serbia
Role of membranes mechanisms (omega-3 unsaturated fatty acids and connexin-43) in pathology of cardiovascular diseases
Duration: 1. 1. 2008 - 31. 12. 2013
Evidence number:
Program: Medziakademická dohoda (MAD)
Project leader: RNDr. Tribulová Narcisa, DrSc.
Annotation: no description
Partner countries: Ukraine
RIFAOM - The effect of lifestyle-related risk factors on the intrinsic defensive mechanisms in the myocardium
Duration: 1. 1. 2012 - 31. 12. 2013
Evidence number: APVV SK-CZ-0199-11
Program: Medzivládna dohoda
Project leader: MUDr. Ravingerová Táňa, DrSc., FIACS
SAS cosolvers: RNDr. Čarnická Slávka, PhD, Mgr. Farkašová Veronika, PhD, Ing. Ferko Miroslav, PhD., Mgr. Muráriková Martina, PhD., Ing. Ziegelhöffer Attila, DrSc.
Annotation: Lifestyle-related risk factors (RF), such as hypertension, hyperglycemia and dyslipidemia, have a negative impact on the heart exposed to ischemia: they increase its lethal injury (infarction) and incidence of sudden death due to malignant ventricular arrhythmias. However, some stressful factors, e.g., free radicals and high glucose might play a dual role in the mechanisms of ischemia-reperfusion injury (IRI) and except deleterious effects induce adaptive processes stimulating mechanisms of the heart´s own defense against IRI. Increased ischemic tolerance occurring in the frames of pleiotropic (independent of primary) effects of some hypolipidemic and antidiabetic drugs is characteristic for female heart and declines with age in both genders. Although efficiency of adaptation may be reduced by lifestyle-related comorbidities, the effect of RF has not been definitely proven. It has been shown that even pathologically altered myocardium need not loose its ability to be adapted although it requires a greater intensity of an adaptive stimulus. Our aim is to verify the hypothesis that RF of lifestyle alter cardiac response to acute ischemia not only by interference with pathophysiological mechanisms of IRI, but also by suppression of intrinsic adaptive processes in the myocardium and its ability to tolerate ischemia. The project is focused on the study of the effects of mentioned RF on cellular defense mechanisms in relationship with gender differences and aging, as well as on the possibilities to restore adaptive potential of the heart in subjectes challenged with several RF by reactivation of adaptive processes in the myocardium and increase in ischemic tolerance. Anticipated results may contribute to elective utilization of adaptive mechanisms in the myocardium with the aim to suppress unwanted effects of RF and to optimize antiischemic therapy taking into consideration the gender- and aging-related effects on the mechanisms of cardiac ischemic tolerance.
Partner countries: Czech Republic
Effect of natural polyphenols on the development and maintenance of experimental hypertension and remodelling of cardiovascular system
Duration: 1. 10. 2004 - 30. 9. 2013
Evidence number:
Program: Medziústavná dohoda
Project leader: doc. RNDr. Pecháňová Oľga, DrSc.
SAS cosolvers: MVDr. Barta Andrej, PhD., RNDr. Bernátová Iveta, DrSc., RNDr. Kopincová Jana, MUDr. RNDr. Púzserová Angelika, PhD., RNDr. Vranková Stanislava, PhD.
Annotation: no description
Partner countries: France
Detecting evolutionary hot spots of antibiotic resistances in Europe
Duration: 23. 9. 2009 - 22. 9. 2013
Evidence number: Action TD0803
Program: COST
Project leader: Ing. Ďurišová Mária, DrSc.
Annotation: The main objective of DARE is to identify and characterize environmental hot spots for antimicrobial resistance emergence and spreading of antibiotics and antibiotic resistance patterns, aiming at the development of measures to control antibiotic resistance evolution.
PHWORK - Promoting Healthy Work for Employees with Chronic Illness - Public Health and Work
Duration: 1. 9. 2011 - 31. 8. 2013
Evidence number: EAHC No 20101208
Program: Multilaterálne - iné
Project leader: MUDr. Jagla Fedor, CSc.
SAS cosolvers: doc. RNDr. Pecháňová Oľga, DrSc.
Other cosolvers: University Medical
Annotation: The proposed project will contribute towards the implementation of effective workplace health practices within corporate policies of enterprises in Europe, aimed at retaining and encouraging the return-to-work (RTW) of chronically ill employees.
Partner countries: Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Malta, Netherlands, Norway, Portugal, Romania, Slovenia, Spain
Recent advances in histamine receptor H4R research
Duration: 9. 4. 2009 - 8. 4. 2013
Evidence number: Action BM0806
Program: COST
Project leader: prof. MUDr. Nosáľ Radomír, DrSc.
Annotation: COST Action BM0806 is a broad research group with multidisciplinary approach focusing on the research of H4 histamine receptor. The H4 histamine receptor is known from the year 2000 and it is likely to be involved in hematopoiesis, immune cells regulation or inflammation. Pre-clinical data suggest involvement of H4 histamine receptors and their agonists/antagonists in regulation of allergy, inflammation, autoimmune diseases and cancer.The Action COST BM0806 comprises 4 different groups:1/ Methodological approaches for H4R systems investigation2/ (Patho)physiological importance of H4R systems3/ Pharmacological properties of new selective H4R ligands4/ Therapeutic potential of new H4R histaminergic compounds.We are investigating the involvement of histamine H4 receptor agonists and antagonists in the regulation of activated human neutrophils (working group 2).
Partner countries: Austria, Brazil, Czech Republic, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Lithuania, Netherlands, New Zealand, Poland, Serbia, Slovenia, Spain, Sweden, Switzerland, United Kingdom
Chronic ischemic injury of the heart: Influence of ionizing radiation on cardiovascular system and possibilities to minimize its adverse effect
Duration: 1. 1. 2007 - 31. 12. 2012
Evidence number:
Program: Bilaterálne - iné
Project leader: D.h.c., Prof., MUDr. Slezák Ján, DrSc., FIACS
SAS cosolvers: MUDr. Ravingerová Táňa, DrSc., FIACS, RNDr. Tribulová Narcisa, DrSc., Ing. Ziegelhöffer Attila, DrSc.
Other cosolvers: Prof. Pawan Singal, Prof. Grant Pierce, Prof. Naranjan Dhalla
Partner countries: Canada
In vitro and in vivo models of arthritic processes for studying the mechanisms of inflammation and oxidative stress link-up. New perspectives for arthritis therapy
Duration: 1. 1. 2010 - 31. 12. 2012
Evidence number: CNR-SAV
Program: Bilaterálne - iné
Project leader: PharmDr. Bauerová Katarína, PhD., DrSc.
Partner countries: Italy
Regulation of cytokine synthesis during inflammation develoment in brain and other tissues
Duration: 1. 1. 2010 - 31. 12. 2012
Evidence number: RAMS-SAV
Program: Bilaterálne - iné
Project leader: PharmDr. Bauerová Katarína, PhD., DrSc.
Partner countries: Russia
2 VPH NoE - Virtual Physiological Human, Network of Excellence, 7FP WU
Duration: 1. 5. 2009 - 31. 12. 2012
Evidence number: 223920, FP7-ICT-2007-2
Program: 7RP
Project leader: Ing. Ďurišová Mária, DrSc.
SAS cosolvers: Ing. Ďurišová Mária, DrSc.
Other cosolvers: London\'s global university, London; University of Oxford, Oxford; CNRS, Paris cedex; Universite Libre de Bruxelles, Brussels; INRIA Paríž; University Pompeu Fabra, Barcelona; •University of Auckland, Auckland; European Molecular Biology Laboratory, Heidelberg; University of Sheffield, Sheffield; Karolinska Institutet, Stockholm; Institut Municipal d\'Assistència Sanitària, Barcelona; ERCIM, Sophia Antipolis Cedex; University of Bedfordshire, Bedfordshire; Istituto Ortopedico Rizzoli, Bologna; •University of Padova, Padova; Istituto di Ingegneria Biomedica, Rím; University of Amsterdam, Amsterdam; Technical University of Denmark, Lyngby; Aalborg University, Aalborg; Zuse Institute Berlin, Berlin; Helmholtz-Institute for Biomedical Engineering, Aachen; CIGENE - Norwegian University of Life Sciences, Oslo; Institute of Bioengineering of Catalonia, Barcelona; University of Barcelona Biomedical Institute, Barcelona; University of Melbourne, Melbourne; Aristotle University of Thessaloniki, Thessaloniki; Institut National de Recherche sur les Transports et leur Sécurité, Lyon; Instituto de Engenharia Mecânica, Porto; University of Zagreb, Zagreb; Univ. Politecnica Madrid, Madrid; Charité – Universitätsmedizin, Berlin; Franhofer Institute for Algorithms and Scientific Computing, Mníchov; University Medical Center, part of Vereniging VU-Windesheim, Windesheim; University of Camerino, Camerino; University di Bologna, Bologna; Politecnico di Milano, Milano
Annotation: A study, mathematical modeling, and simulations of physiological processes on whole-body, tissue, and cellular level under physiological conditions and also under pathological conditions. A study of possible pharmacological influences of studied processes under pathological conditions.
Partner countries: Australia, Belgium, Croatia, Denmark, France, Germany, Greece, Italy, Netherlands, New Zealand, Norway, Portugal, Spain, Sweden, United Kingdom
Project website: http://www.vph-noe.eu/
Antibiotic transport and efflux: new strategies to combat bacterial resistance
Duration: 8. 1. 2008 - 18. 5. 2012
Evidence number: Action TD0803
Program: COST
Project leader: Ing. Ďurišová Mária, DrSc.
SAS cosolvers: Ing. Ďurišová Mária, DrSc.
Annotation: Constructions of mathematical models describing transport and efflux processes in the development of new strategies to combat against antibiotic resistance. Utilization of an original methodologically, conceptually, and computationally uniform approach to constructions of mathematical models.
Partner countries: Austria, Belgium, Denmark, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Latvia, Lithuania, Norway, Poland, Portugal, Romania, Spain, Switzerland, Turkey, United Kingdom
Project website: www.uef.sav.sk/durisova.htm
The role of nitric oxide, free radicals, and AII peptide on vascular structure and function in experimental hypertension.
Duration: 1. 3. 2010 - 31. 12. 2011
Evidence number: SK-SRB-0026-09
Program: Bilaterálne - iné
Project leader: RNDr. Kristek František, DrSc.
SAS cosolvers: RNDr. Čačányiová Soňa, PhD.
Annotation: Chronic NO deficiency due to inhibition of constitutive NO-synthase (NOS) by NG-nitro-L-arginine methylester (L-NAME) results in sustained increase of blood pressure accompanied with cardiac and arterial wall hypertrophy. 7-nitroindazole (7-NI), a potent and selective inhibitor of neuronal NO-synthase (NOS), contrary to L-NAME administration, did not provide unequivocal effect on the efficiency of the cardiobvascular system. Moreover, the studies devoted to comparison of the integrated responses and mainly underlying structural alterations of the heart and vascular system evoked by these two types of NOS inhibitors are completely missing. Also, special emphasis will be focused on the role of free radicals and renin-angiotensin system (RAS) in mentioned disorders.
Ochrana srdca - Omega-3 index and disclosure the novel mechanisms of omega-3 fatty acids actions involved in cardiac disease and arrhythmia protection.
Duration: 1. 1. 2010 - 31. 12. 2011
Evidence number: SK-UA-0022-09
Program: Medzivládna dohoda
Project leader: RNDr. Tribulová Narcisa, DrSc.
SAS cosolvers: RNDr. Barančík Miroslav, DrSc., Ing. Ivanová Monika, PhD., RNDr. Okruhlicová Ľudmila, CSc., doc. MUDr. Radošinská Jana, PhD., RNDr. Szeiffová Bačová Barbara, PhD., Ing. Šimončíková Petra, PhD.
Annotation: In agreement with the concept of health care in the field cardiology the specific goal of the project is to provide further evidence supporting the role of omega-3 fatty acids in primary and secondary prevention of cardiovascular diseases that are major causes of morbidity and mortality worldwide. There are several goals of the projects: 1) To elaborate and introduce the method for the assay of a new risk factor of cardiovascular diseases, omega-3 index, and to monitor its changes in relationship to injury of the heart and its vulnerability to lethal arrhythmias in experimental rat models characterized by hypertriglyceridemia, hypertension, diabetes, ischemia; 2) To monitor omega-3 index in humans suffering from another risk factors such as overweight, dyslipidemia, hypertension, insulin resistance while focusing on impact of age (children and adolescent versus older individuals) and gender in Slovak and Ukraine population; 3) To reveal a new cellular and molecular mechanisms involved in omega-3 fatty acids protection against cardiac injury and malignant arrhythmias by using laboratory equipments and methodological potential of both institutions. In this context the investigation will focus on the effects of omega-3 fatty acids on cell-to-cell communication ensured by intercellular connexin channels and intracellular signalling mediated by protein kinases and NO as well as on the effect of omega-3 fatty acids on target proteins gene expression via nuclear PPAR receptors; 4) To prepare findings for publications in CC journals as well as for presentations on cardiological and other congresses to support by this way the impact of diet-therapy; 5) To elaborate project proposal for the possibility to participate in international research programmes. There is an assumption that results will be used in „the evidence based medicine“, in the screening of individuals with a risk of cardiovascular diseases as well as in the prevention of sudden cardiac death
Partner countries: Ukraine
Investigation of factors determining malignant arrhythmias and their prevention by omega-3 fatty acids in cardiomyopathic rats.
Duration: 1. 1. 2009 - 31. 12. 2011
Evidence number:
Program: Medziakademická dohoda (MAD)
Project leader: RNDr. Tribulová Narcisa, DrSc.
Annotation: no description
Partner countries: Czech Republic
Sensory biofeedback for human balance improvement
Duration: 1. 9. 2010 - 31. 8. 2011
Evidence number: 2010-03-15-0004
Program: Medzivládna dohoda
Project leader: Ing. Hlavačka František, CSc.
SAS cosolvers: Mgr. Hirjaková Zuzana, PhD., RNDr. Kimijanová Jana, PhD., Mgr. Šuttová Kristína, PhD., Prof. MUDr. Valkovič Peter, PhD.
Other cosolvers: FTVŠ UK, Doc. Mgr. Erika Zemková, PhD.
Annotation: The project is a first step of bilateral Austrian-Slovak collaboration in the field of human posture and gait control. Loss of balance leading to falls is a primary cause of injury and accidents in elderly. A better understanding the ways of balance and gait improvement using body sway feedback is perspective to prevent postural instability and falls in seniors and to innovate rehabilitation method of balance disorders. The overall aim of the project is to inform each other about methods of all collaborating laboratories, to perform a preliminary experiment and to prepare common research project with main participation of young scientists.
Partner countries: Austria
Improvement and development of high-resolution ECG measurement processing and evaluation methods.
Duration: 1. 4. 2011 - 15. 6. 2011
Evidence number: TÁMOP-4.2.2-08/1/2008-0018
Program: Bilaterálne - iné
Project leader: RNDr. Szathmáry Vavrinec, CSc.
Annotation: 1. Modeling of beat-to-beat variations of ventricular activation and repolarization by the numerical heart model elaborated in the Institute previously.2. The beat-to-beat variations should model the effect of the pathological changes in the Purkinje-myocardium connections by the systematic turn-off of the endocardial activation initiation junctions.3. In order to achieve an adequate representation of repolarization properties, the local action potential duration shortening or prolongation around the activation initiation points should be taken into account.4. Activation and recovery patterns should be represented by propagation maps in vertical and horizontal cross-sections. Furthermore the corresponding orthogonal ECG plots should be attached.5. Propagation model data should be further processed in cooperation with the Institute of Measurement Science, SAS, Bratislava, in order to provide body surface potential distribution maps.6. All the papers published from the results of this cooperation will have a common list of authors with the Slovakian partners. The list of authors will be finalized before the paper submissions.
Study of the adaptive mechanisms in the heart during ischemic injury: novel possibilities of cardioprotection.
Duration: 1. 6. 2010 - 30. 5. 2011
Evidence number:
Program: Medziakademická dohoda (MAD)
Project leader: MUDr. Ravingerová Táňa, DrSc., FIACS
SAS cosolvers: doc. RNDr. Barteková Monika, PhD., RNDr. Čarnická Slávka, PhD, RNDr. Matejíková Jana, PhD., RNDr. Nemčeková Martina, Ing. Pancza Dezider, MUDr. Styk Ján, CSc., Ing. Ziegelhöffer Attila, DrSc.
Annotation: A new project of bilateral collaboration that was prepared in 2010 and approved in the frames of the Agreement on collaboration between SAS and RAMS. The project starts in 2011 and is focused on the study of the adaptive processes in the heart on the level of cell signaling mechanisms from receptors through postreceptor pathways up to the final targets in mitochondria and their elective utilization in the protection of ischemic myocardium. In particular, it will target myocardial protection against lethal injury (myocardial infarction), contractile dysfunction and ventricular arrhythmias on the experimental model of ischemia/reperfusion injury of the heart.
Partner countries: Russia
The role of oxidative stress in apoptosis and dysfunction of pancreatic beta cells. The potential protective effect of novel pyridoindole antioxidants.
Duration: 1. 4. 2009 - 30. 4. 2011
Evidence number: 103S180
Program: Bilaterálne - iné
Project leader: Ing. Štefek Milan, CSc.
SAS cosolvers: Prof. MUDr. Bauer Viktor, DrSc., RNDr. Horáková Ľubica, PhD., Ing. Račková Lucia, PhD., RNDr. Sotníková Ružena, CSc.
Other cosolvers: P
Annotation: The investigation of potential participation of reactive oxygen species in the apoptotic pathways of pancreatic beta cells involved in diabetes type 1 and type 2; evaluation of potential protective effect of novel pyridoindole derivatives on apoptosis and beta cell dysfunction in pancreatic INS-1E cell culture lines and in an in vivo model of autoimmune diabetes.
Partner countries: Turkey
EEG analysis of memory processes and emotional events.
Duration: 1. 9. 2010 - 31. 1. 2011
Evidence number: 51001195
Program: International Visegrad Found (IVF)
Project leader: RNDr. Cimrová Barbora, PhD.
Annotation: Clarification of memory processes involved in processing of emotional events. Analysis of functional connectivity of the brain during the recollection of anxiety related situation.
Partner countries: Czech Republic
Analysis of the central electrophysiological correlates in relation to anxiety
Duration: 1. 11. 2005 - 31. 12. 2010
Evidence number:
Program: Medziústavná dohoda
Project leader: MUDr. Jagla Fedor, CSc.
SAS cosolvers: MUDr. Jagla Fedor, CSc., MUDr. Riečanský Igor, PhD.
Other cosolvers: K
Annotation: no description
Partner countries: Czech Republic, Slovakia
Association of myeloperoxidase with hyaluronan. Implications for the pathophysiology of rheumatoid arthritis.
Duration: 1. 1. 2009 - 31. 12. 2010
Evidence number: D/08/07735
Program: Bilaterálne - iné
Project leader: Ing. Šoltés Ladislav, DrSc.
Other cosolvers: Prof. Dr. Jürgen Arnhold
Annotation: High-molecular weight hyaluronan (HA) from different origin will be incubated with fluorescently-labeled myeloperoxidase (MPO) in order to evaluate parameters of associate formation and consequences for the initiation of HA degradation. Polymorphonuclear leukocytes are known to invade in huge amount into inflamed joints during rheumatoid arthritis where they release the cationic myeloperoxidase. Associate formation will be followed by fluorescence correlation spectroscopy, while HA degradation will be followed by changes in viscosity as measured by rheometry/rotational viscometry. In addition, MALDI-TOF mass spectrometry, NMR spectroscopy techniques and chemiluminescence measurements will be applied.From these investigations, we expect to get new information about pathophysiological processes of HA degradation as well as regulation of the inflammatory process. A better understanding of these fundamental reactions will improve our knowledge as well as the search for new strategies of drug application. A further goal is to establish a reliable Experimental Study Protocol for classification of inhibitors of the hyaluronan degradation caused by oxidants – at various experimental conditions. The Protocol will allow in future to provide an exact mode of classification of prospective drugs as inhibitors of HA oxidative damage in association with the binding of myeloperoxidase to HA subunits.
Partner countries: Germany
Physiological, pharmacological, morphological and molecular studies on the role of myocardial gap junctions in initiation and termination of cardiac arrhythmias
Duration: 1. 1. 2000 - 31. 12. 2010
Evidence number:
Program: Bilaterálne - iné
Project leader: RNDr. Tribulová Narcisa, DrSc.
Annotation: no description
Partner countries: Japan
Co-operation in postgraduate education
Duration: 1. 1. 2008 - 31. 12. 2010
Evidence number:
Program: Medziústavná dohoda
Project leader: doc. RNDr. Pecháňová Oľga, DrSc.
SAS cosolvers: MUDr. Jagla Fedor, CSc.
Other cosolvers: D.P.Dvoretsky - I.P.Pavlov Institute of Physiology, RAS, St.Petersburg
Annotation: no description
Partner countries: Russia
Study of arrhythmogenic and antiarrhythmic mechanisms in the myocardium
Duration: 1. 1. 1993 - 31. 12. 2010
Evidence number:
Program: Bilaterálne - iné
Project leader: RNDr. Tribulová Narcisa, DrSc.
Annotation: no description
Partner countries: Israel
Role of membrane mechanisms (omega-3 fatty acids and connexin-43) in pathology of cardiovascular disease
Duration: 1. 1. 2008 - 31. 12. 2010
Evidence number:
Program: Medziakademická dohoda (MAD)
Project leader: RNDr. Tribulová Narcisa, DrSc.
SAS cosolvers: Ing. Frimmel Karel, PhD., RNDr. Okruhlicová Ľudmila, CSc., doc. MUDr. Radošinská Jana, PhD., RNDr. Szeiffová Bačová Barbara, PhD.
Annotation: Elucidation of the mechanisms of the cardioprotective effects of omega-3 fatty acids on the connexin-43 in cell membranes of the cardiomyocytes
Partner countries: Ukraine
The effect of natural polyphenols on the damage of cardiovascular system and kidney indiced by long-term cyclosporine A treatment
Duration: 1. 1. 2007 - 31. 12. 2010
Evidence number:
Program: Medziústavná dohoda
Project leader: doc. RNDr. Pecháňová Oľga, DrSc.
SAS cosolvers: MVDr. Barta Andrej, PhD., MUDr. Janega Pavol, PhD, MUDr. RNDr. Paulis Ľudovít, PhD. MPH., RNDr. Vranková Stanislava, PhD.
Annotation: no description
Partner countries: Italy
Electrophysiology of cognition - a common research focus
Duration: 1. 11. 2007 - 31. 10. 2010
Evidence number:
Program: Medziústavná dohoda
Project leader: MUDr. Riečanský Igor, PhD.
Annotation: Bilateral cooperation includes mutual study visits, sharing of methodological resources and experimental data, preparation and accomplishment of common experiments and preparation of shared publications.
Partner countries: Austria
Neural signatures of the saccadic efference copy feedback signal
Duration: 1. 1. 2010 - 30. 6. 2010
Evidence number:
Program: Medzivládna dohoda
Project leader: MUDr. Riečanský Igor, PhD.
Annotation: The project is focused at the exploration of brain mechanisms of motor command feedback information, termed efference copy. To this aiman electroencephalography (EEG) study will be carried out employing the double-step saccades paradigm, which relies on the integration of theefference copy with the ongoing neural processing within the oculomotor system. The project will yield novel information about the brain mechanisms of sensorimotor transformation and spatial cognition in general.
Partner countries: Austria
Lipid peroxidation associated disorders
Duration: 1. 6. 2006 - 30. 6. 2010
Evidence number: B35
Program: COST
Project leader: RNDr. Horáková Ľubica, PhD.
Annotation: no description
Partner countries: Austria, Belgium, Croatia, Czech Republic, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Latvia, Lithuania, Poland, Romania, Spain, Sweden, Turkey, United Kingdom
BioSim - Biosimulation – A New Tool in Drug Development
Duration: 1. 12. 2004 - 30. 3. 2010
Evidence number: LSHB-CT-2004-005137
Program: 6RP
Project leader: Ing. Ďurišová Mária, DrSc.
SAS cosolvers: Ing. Ďurišová Mária, DrSc.
Other cosolvers: P
Annotation: Development and utilization of methods based on the theory of linear dynamic systems for modeling and simulations of effect and behavior of drugs in the body.
Partner countries: Belgium, Denmark, France, Germany, Hungary, Netherlands, Slovakia, Spain, Sweden, United Kingdom
Project website: http://biosim.fysik.dtu.dk:8080/biosim/index.jsp
Degradative action of reactive oxygen species on hyaluronan: Degradation kinetics and molecular characteristics of generated hyaluronan fragments
Duration: 1. 1. 2007 - 31. 12. 2009
Evidence number: SAS/CNR No.: 132.48.1
Program: Medziakademická dohoda (MAD)
Project leader: Ing. Šoltés Ladislav, DrSc.
Annotation: High-molecular weight hyaluronan (HA) will be incubated with free metal ions, oxidants and oxidant generating systems that reflect the redox environment in inflamed joint in order to better understand fundamental processes of HA degradation occurring at inflammatory loci under pathological conditions such as rheumatoid arthritis where a large number of polymorphonuclear leukocytes is being accumulated. As the most appropriate analytical methods the rheometry/rotational viscometry, SEC-MALS, HPLC techniques will be applied. A further goal is to establish a reliable Experimental Study Protocol for classification of inhibitors of the hyaluronan degradation caused by oxidants – at various experimental conditions. The Protocol will allow in future to provide an exact mode of classification of prospective drugs as inhibitors of HA oxidative damage caused by oxidant(s). The implementation of the results would expand the knowledge of drug action and in this way would ensure the maximum safety for the treated patients. The main application of the novel knowledge will be in the health management and the benefiting subjects will be the patients. Further potential applications of the acquired knowledge will be in environment protection, human nutrition, etc.The results, which will have a potential to be patented, will be selected for the negotiation with potential users and then patented with their financial support in order to ensure in this way that the economical profit will come to co-operating Italian-Slovak Institutions.
Partner countries: Italy
Cortical dynamics in the programming of double step saccades
Duration: 7. 7. 2008 - 31. 12. 2009
Evidence number: SR-RU-0009-07
Program: Medzivládna dohoda
Project leader: MUDr. Riečanský Igor, PhD.
SAS cosolvers: MUDr. Jagla Fedor, CSc.
Annotation: Saccades are rapid eye movements, which enable us to explore the visual scene and interact dynamically with the environment. Therefore, the neural mechanisms of saccadic eye movement programming are intensely studied. Generation of single saccades is based on the information about position of the peripheral target. In a double-step paradigm, the target changes its position rapidly, before the preceding (first) saccade has been executed, so that the (second) saccade cannot be based on simple visuotopic retinal information about the target position, but must take into account the preceding saccadic eye movement, i.e. the efference copy of the motor command. The nature of the efference copy and its role in sensorimotor integration in normal and pathological states is currently much debated. Saccadic eye movement related potentials (SEMRPs) enable to study the brain dynamics underlying the generation of saccades with high temporal precision. Analysis of SEMRPs recorded during execution of double-step saccades will provide valuable information about the neural mechanisms of the efference copy feedback signal and will shed light on important aspects of sensorimotor integration in the brain. These findings will be of general interest in the field of cognitive neuroscience and neuropsychiatry.
Partner countries: Russia
Different models of experimental hypertension and their vasoactive systems
Duration: 1. 1. 2005 - 31. 12. 2009
Evidence number:
Program: Medziústavná dohoda
Project leader: doc. RNDr. Pecháňová Oľga, DrSc.
SAS cosolvers: MVDr. Barta Andrej, PhD., RNDr. Klimentová Jana, PhD., MUDr. RNDr. Paulis Ľudovít, PhD. MPH., RNDr. Vranková Stanislava, PhD.
Other cosolvers: Lekárska fakulta UK, Bratislava
Annotation: The aim of the project is the study of vasoactive balance, namely the activation of sympathetic nervous system, renin-angiotensin-aldosteron system and the level of reactive oxygen and nitrite species within the different models of hypertension in chronic and acute conditions.
Partner countries: Czech Republic, Slovakia
Noninvasive elektrophysiological investigation of the heart on the basis of mathematical modelling
Duration: 1. 1. 2007 - 31. 12. 2009
Evidence number:
Program: Medziústavná dohoda
Project leader: RNDr. Szathmáry Vavrinec, CSc.
SAS cosolvers: RNDr. Regecová Valéria
Annotation: no description
Partner countries: Russia
Portable system for the investigation and conditionig of human posture control
Duration: 1. 1. 2007 - 31. 12. 2009
Evidence number:
Program: Medziakademická dohoda (MAD)
Project leader: Ing. Hlavačka František, CSc.
SAS cosolvers: RNDr. Bzdúšková Diana, PhD., RNDr. Čapičíková Naďa, PhD.
Annotation: The overall goals of this project are:1) to develop a portable device for monitoring human posture control.2) to validate the implementation of the sensory biofeedback used in the portable system for improvement and rehabilitation of human imbalance.Loss of balance and mobility is a significant social problem especially in the elderly because it can lead to dangerous falls, injuries and consequent social exclusion. Maintaining body balance requires the integration of sensory information from the vestibular system in the inner ear, vision, and the somatosensory system. The brain interprets these sensory signals to estimate the position of the body. Our aim is to help, by means of a portable system incorporating sensory biofeedback device, to compensate deficit of vestibular or somatosensory function to improve balance in the upright posture.
Partner countries: Italy
Improvement of the cardiovascular system understanding with the aim to improve diagnostics and treatment of cardiac patients
Duration: 1. 1. 2007 - 31. 12. 2009
Evidence number:
Program: Medziústavná dohoda
Project leader: RNDr. Szathmáry Vavrinec, CSc.
SAS cosolvers: Doc. Ing. Tyšler Milan, CSc.
Other cosolvers: Assoc. Prof. Kozmann György, DrSc.
Annotation: no description
Partner countries: Hungary
Sensory integration in spatial orientation for stance and gait
Duration: 1. 1. 2004 - 31. 12. 2009
Evidence number:
Program: Medziústavná dohoda
Project leader: Ing. Hlavačka František, CSc.
SAS cosolvers: RNDr. Bzdúšková Diana, PhD., RNDr. Čapičíková Naďa, PhD., MUDr. Dzurková Oľga
Annotation: no description
Partner countries: Slovakia, United States
Role of blood platelets, neutrophils and extracellular matrix in inflammation. Analysis of drugs and perspective natural compounds
Duration: 1. 2. 2008 - 31. 12. 2009
Evidence number: APVV SK-CZ-0114-07
Program: Medzivládna dohoda
Project leader: prof. MUDr. Nosáľ Radomír, DrSc.
SAS cosolvers: PharmDr. Jančinová Viera, PhD., RNDr. Mačičková Tatiana, CSc., RNDr. Pečivová Jana, PhD., Mgr. Perečko Tomáš , PhD.
Other cosolvers: Doc. RNDr. A. Lojek, PhD.
Annotation: Oxidative stress and proinflammatory processes are involved in many pathophysiological diseases. Interaction of neutrophils and blood platelets, increased production of biologically active compounds as well as interaction with intercellular matrix (collagen) play an important role in inflammation. The hypothesis of mutual collaboration of collagen, blood platelets and neutrophils on modulation of oxidative burst of phagocytes and extent of inflammatory process will be assessed. Simultaneously effect of natural compounds and therapeutically used drugs will be tested on the functions of blood platelets and neutrophils.
Partner countries: Czech Republic
To work out new methods for noninvasive determination of electrophysiological state of the heart with aim to improve cardiac diagnostics, using mathematical and computer modelling
Duration: 1. 10. 2006 - 31. 12. 2009
Evidence number:
Program: Medziústavná dohoda
Project leader: RNDr. Szathmáry Vavrinec, CSc.
Annotation: no description
Partner countries: Russia
ABAP - Activation of cellular adaptive processes as a potential target of cardiac protection against ischaemic injury
Duration: 1. 1. 2008 - 1. 12. 2009
Evidence number: APVV SK-CZ-0049-07
Program: Medzivládna dohoda
Project leader: MUDr. Ravingerová Táňa, DrSc., FIACS
SAS cosolvers: doc. RNDr. Barteková Monika, PhD., RNDr. Čarnická Slávka, PhD, Ing. Ferko Miroslav, PhD., RNDr. Matejíková Jana, PhD., RNDr. Mujkošová Jana, MUDr. Styk Ján, CSc., Ing. Ziegelhöffer Attila, DrSc.
Other cosolvers: Fyziologický ústav AV ČR, Praha, ČR - Prof. RNDr. F. Kolář, CSc., Prof. B. Ošťádal, Dr. I. Ošťádalová, Dr. G. Borchert, Dr. J. Neckář, Dr. D. Stakheev, Mgr. K.
Partner countries: Czech Republic
Development of new methods coming from the linear dynamic systems for simulation and mathematical modelling of in drug development
Duration: 1. 1. 2005 - 30. 11. 2009
Evidence number: LSHB-CT-2004-005137
Program: 6RP
Project leader: Ing. Ďurišová Mária, DrSc.
SENSACTION-AAL - SENSing and ACTION to support mobility in Ambient Assisted Living
Duration: 1. 1. 2007 - 1. 10. 2009
Evidence number: FP6 - 045622
Program: 6RP
Project leader: Ing. Hlavačka František, CSc.
SAS cosolvers: RNDr. Bzdúšková Diana, PhD., RNDr. Čapičíková Naďa, PhD., Ing. Hlavačka František, CSc., Ing. Mihálik Viliam
Annotation: The SENSACTION-AAL project offers the opportunity for a significant advancement of the state-of-the-art in the field of ambulatory assisting devices for enhancing safety and security in balance and movement. The ultimate goal of the project is to assist older people in maintaining independent mobility and daily life activities and prevent injuries by introducing smart body fixed sensor based technology that allow medical professionals to initiate interventions in the home environment. To achieve this goal, the SENSACTION-AAL project will design, test and release a next-generation, smart, wireless on-body system which enables: (1) monitoring of activities of daily living and (2) simultaneous real-time active control of physical performance using principles such as sensory augmentation and biofeedback. This system is equipped with both biosensors and bioactuators in-the-loop. The SENSACTION-AAL architecture will introduce new ICT solutions that make the proposed system: 1) easy-to-wear and easy-to-use; 2) active anywhere, anytime; 3) cost effective.SENSACTION-AAL will develop an ICT-based solution which is highly usable and can support the elderly people in their preferred environment. The key challenge is to develop an integrated system that brings together the different components involved (network cells; communication protocols; embedded real-time algorithms for actuator control; signal processing algorithms; data warehousing, web-based data access). An extended in-vivo accurate validation carried out with the support of end-users is also foreseen to assess the satisfaction of key user requirements and produce a solution which is adequate for industrial take-up.Ultimately, this project could have important influences on the quality of life of European citizens. These new systems will empower persons with disabilities and aging citizens to play a major role in society and will help them to augment their autonomy and realize their potential.
Partner countries: Germany, Israel, Italy, Netherlands, Slovakia, Spain
Project website: www.sensaction-aal.eu
Physiologically based Pharmaco-Toxicokinetics and Dynamics
Duration: 1. 4. 2007 - 31. 5. 2009
Evidence number:
Program: COST
Project leader: Ing. Ďurišová Mária, DrSc.
SAS cosolvers: Ing. Ďurišová Mária, DrSc.
Annotation: Development and utilization of new methods based on the linear dynamic system theory for the mathematical modeling of effect and behavior of drugs in the body.
Partner countries: Belgium, Canada, Czech Republic, Denmark, Finland, France, Germany, Greece, Ireland, Israel, Italy, Malta, Netherlands, Norway, Portugal, Romania, Serbia, Spain, Sweden, Switzerland, Turkey, United Kingdom
Move Europe
Duration: 1. 6. 2006 - 30. 4. 2009
Evidence number: Grant Agreement, 2005303
Program: Multilaterálne - iné
Project leader: MUDr. Jagla Fedor, CSc.
Other cosolvers: zamestnanecké organizácie SR
Annotation: no description
Partner countries: Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Estonia, Finland, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, United Kingdom
Electrophysiological investigations of neural mechanisms underlying imaginary object rotation
Duration: 1. 10. 2008 - 31. 3. 2009
Evidence number: ACM-2008-00688
Program: Medzivládna dohoda
Project leader: MUDr. Riečanský Igor, PhD.
Annotation: This project is aimed at searching for neural correlates of mental rotation, i.e. imaginary object spatial manipulation, which has been widely used to study the nature of spatial cognition and to assess visuo-spatial abilities in human subjects. In our previous study (submitted for publication) we demonstrated that individual performance in mental rotation of letters and digits rotated in the frontal plane was very accurately predicted from the amplitude of the posterior slow negativity in case the signals were time-locked to response latency. This strongly indicates that the parietal negativity is a specific correlate of the mental rotation process. Unfortunately, due to small number of recording channels, these experiments could not assess contribution of parallelly engaged but potentially confounding cognitive processes, especially working memory maintenance. In this study we aim to determine the signatures of brain activity specifically related to (1) maintenance of visual object representation in working memory and (2) spatial manipulations on this representation, i.e. mental rotation. We will perform multichannel event-related electroencephalographic (EEG) recordings and employ novel techniques of bioelectric signal analysis and source reconstruction, which enable us to determine the spatio-temporal patterns of brain activity with high precision. The study will provide important novel insights into the neural basis of spatial cognition and intelligence in general.
Partner countries: Austria
Degradative Action of Reactive Oxygen Species on Hyaluronan: Degradation Kinetics and Molecular Characteristics of Generated Hyaloruronan Fragments
Duration: 1. 1. 2007 - 31. 12. 2008
Evidence number: SAS/DAAD No.: D/06/07383
Program: Medziakademická dohoda (MAD)
Project leader: Ing. Šoltés Ladislav, DrSc.
Annotation: no description
Partner countries: Germany
Protection of ischemic myocardium
Duration: 1. 1. 2006 - 31. 12. 2008
Evidence number:
Program: Medziústavná dohoda
Project leader: MUDr. Ravingerová Táňa, DrSc., FIACS
Annotation: no description
Partner countries: Czech Republic
-
Duration: 1. 1. 2007 - 31. 12. 2008
Evidence number:
Program: Medziakademická dohoda (MAD)
Project leader: MUDr. Styk Ján, CSc.
SAS cosolvers: MUDr. Ravingerová Táňa, DrSc., FIACS
Annotation: no description
Partner countries: Russia
Theoretical and clinical aspects of Na,K-ATPase regulation. Regulation of Na,K-ATPase in adaptation (diabetes mellitus, ischemia)
Duration: 1. 1. 1996 - 1. 1. 2008
Evidence number:
Program: Medziústavná dohoda
Project leader: Ing. Ziegelhöffer Attila, DrSc.
Annotation: no description
Partner countries: Denmark
Antioxidant and antiphagocytic properties of chemical and natural substances and drugs
Duration: 1. 1. 2006 - 31. 12. 2007
Evidence number: 66
Program: Medzivládna dohoda
Project leader: prof. MUDr. Nosáľ Radomír, DrSc.
Annotation: no description
Partner countries: Czech Republic
Modulation of the cardiac icshemic tolerance : the role of endogenous cardioprotective mechanisms.
Duration: 1. 1. 2006 - 31. 12. 2007
Evidence number: SK-CZ 02206
Program: Medzivládna dohoda
Project leader: MUDr. Ravingerová Táňa, DrSc., FIACS
Annotation: no description
Partner countries: Czech Republic
Novel agents for limiting endothelial injury in diabetes mellitus
Duration: 1. 1. 2005 - 31. 12. 2007
Evidence number:
Program: NATO
Project leader: Ing. Ziegelhöffer Attila, DrSc.
SAS cosolvers: MUDr. Ravingerová Táňa, DrSc., FIACS
Annotation: no description
Partner countries: Poland
Electrophysiology of cognition - a common research focus
Duration: 1. 3. 2007 - 30. 10. 2007
Evidence number:
Program: Medzivládna dohoda
Project leader: MUDr. Riečanský Igor, PhD.
SAS cosolvers: MUDr. Jagla Fedor, CSc.
Annotation: Project is aimed at supporting mobility between laboratories oriented on related research topics. It will enable to discuss possibilities of cooperation and coordination of research activities.
Partner countries: Austria
Computational design and preparation of 2,6-difluoro-4-pyrrol-1-yl-phenol derivatives as non-carboxylic acid aldose reductase inhibitors: Preclinical implications for pharmacological prevention of diabetic complication
Duration: 1. 1. 2005 - 30. 6. 2007
Evidence number: GRE 02
Program: Medzivládna dohoda
Project leader: Ing. Štefek Milan, CSc.
Annotation: no description
Partner countries: Greece
Development of antiparasitic drugs
Duration: 1. 2. 2003 - 28. 2. 2007
Evidence number: B22
Program: COST
Project leader: Ing. Ďurišová Mária, DrSc.
Annotation: no description
Partner countries: Austria, Belgium, Bulgaria, Canada, Czech Republic, Denmark, France, Germany, Greece, Ireland, Israel, Italy, Lithuania, Luxembourg, Netherlands, Portugal, Slovakia, Spain, Sweden, Switzerland, United Kingdom
Antioxidants and aldose reductase blockade in prevention of late diabetic complications: study on new pyridoindole derivates
Duration: 1. 1. 2004 - 31. 12. 2006
Evidence number: 2
Program: Medziakademická dohoda (MAD)
Project leader: Ing. Štefek Milan, CSc.
Annotation: no description
Partner countries: Turkey
Comparative study of the degradation of high-molecular-weight hyaluronan by the action of myeoloperoxidase or by the direct action of hypochlorite/hypobromite
Duration: 1. 1. 2005 - 31. 12. 2006
Evidence number:
Program: Medziakademická dohoda (MAD)
Project leader: Ing. Šoltés Ladislav, DrSc.
Annotation: no description
Partner countries: Germany
Intracellular Signalling Pathways and Transcription Factor Activation in Cardiac Adaptation to Ischemia/Reperfusion Injury
Duration: 1. 1. 2005 - 31. 12. 2006
Evidence number: GRE 15
Program: Medzivládna dohoda
Project leader: MUDr. Ravingerová Táňa, DrSc., FIACS
Annotation: no description
Partner countries: Greece
The effect of polyphenolic compounds on the prevention and regression of a tissue damage ba long-term cyclosporine A treatment
Duration: 1. 1. 2004 - 31. 12. 2006
Evidence number:
Program: Medziústavná dohoda
Project leader: doc. RNDr. Pecháňová Oľga, DrSc.
SAS cosolvers: MVDr. Barta Andrej, PhD., MUDr. Janega Pavol, PhD, MUDr. RNDr. Paulis Ľudovít, PhD. MPH., RNDr. Vranková Stanislava, PhD.
Annotation: no description
Partner countries: Italy
Development of new methods of sensory biofeedback for improvment of human balance control
Duration: 1. 1. 2004 - 31. 12. 2006
Evidence number:
Program: Medziakademická dohoda (MAD)
Project leader: Ing. Hlavačka František, CSc.
SAS cosolvers: RNDr. Čapičíková Naďa, PhD.
Annotation: no description
Partner countries: Italy
Development of new methods for the improvment of human balance control: an integrated approach based on modeling techniques and biofeedback devices
Duration: 1. 1. 2001 - 31. 12. 2003
Evidence number:
Program: Medziústavná dohoda
Project leader: Ing. Hlavačka František, CSc.
Annotation: no description
Partner countries: Italy